Interventions, including corticosteroids, melatonin, erythropoietin, anti-TNF-α antibodies, and IL-1rα administration, in clinical use for other diseases, may be also utilized for the control of neurological disorders in susceptible neonates (103–107). The gene discussed is IL6R; the disease is nervous system disorder.